Cantor Fitzgerald Suspends Neutral Rating on Crinetics Pharmaceuticals
Cantor Fitzgerald suspends Neutral rating on Crinetics Pharmaceuticals (NASDAQ:CRNX).
Stocks · News reference
US stocks traded mixed, with the Dow gaining over 200 points as healthcare shares jumped and information technology stocks fell. Trade deficit rose.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cantor Fitzgerald suspends Neutral rating on Crinetics Pharmaceuticals (NASDAQ:CRNX).
Filed: 2026-09-01 AccNo: 0001140361-26-035195 Size: 483 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Business Outlook and Conference CallIn light of Crinetics’ July 6, 2026 announcement regarding the proposed transaction with Vertex, Crinetics will not be providing updated guidance and is withdrawing its previously
DigitalOcean's CFO Matt Steinfort sold 35,151 shares for approximately $3.8 million between September 1-3, 2026. Of these, 25,151 shares were sold to cover tax withholding obligations from RSU vesting, while 10,000 shares were sold under a pre-established Rule 10b5-1 trading plan. The CFO retains over 503,000 shares worth $55.1 million. The stock has surged 241% over the past year, driven by 29% sales growth in Q2 2026 to $281 million, boosted by AI demand.
Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.